Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression

European Neuropsychopharmacology

Volumn 17, Issue 12, 2007, Pages 774-780

  Taler, Michal ^a   Gil Ad, Irit ^a   Lomnitski, Liat ^b   Korov, Inna ^a   Baharav, Ehud ^c   Bar, Meytal ^a   Zolokov, Amichay ^a   Weizman, Abraham ^a,d  

^a TEL AVIV UNIVERSITY   (Israel)

^b Perrigo Israel Pharmaceutical Ltd   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Cytokines; Immune system; SSRI; T cells

Indexed keywords

CYCLOOXYGENASE 2; DEXAMETHASONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IMMUNOMODULATION; INHIBITION KINETICS; LYMPHOCYTE FUNCTION; MICROARRAY ANALYSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL;

ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; CELL SURVIVAL; CELLS, CULTURED; CYCLOOXYGENASE 2; CYTOKINES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; INHIBITORY CONCENTRATION 50; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 35348896483     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.03.010     Document Type: Article

References (41)

1. Ahmed S.A., Gogal R.M., and Walsh J.E. A new rapid and simple non-radioactive assay to monitor and determine proliferation of lymphocytes: an alternative to {3H}thymidine incorporation assay. J. Immunol. Methods 170 (1994) 211-224
2. Anderson G.M., Benett A.J., Weld K.P., Pushas J.G., Ocame D.M., and Higley J.D. Serotonin in cisternal cerebrospinal fluid of rhesus monkeys: basal levels and effects of sertraline administration. Psychopharmacology (Berl) 161 1 (2002) 95-99
3. Aaronson D.S., and Horvath C.M. A road map for those who know JAK-STAT. Science 296 (2002) 1653-1655
4. Barkan T., Gurwitz D., Levy G.T., Weizman A., and Rehavi M. Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. Eur. Neuropsychopharmacol. 14 (2004) 237-243
5. Berkelley M.B., Daussin S., Hernandez M.C., and Bayer B.M. In vitro effects of cocaine, lidocaine and monoamine uptake inhibitors on lymphocyte proliferative responses. Immunopharmacol. Immunotoxicol. 16 (1994) 165-178
6. Breyer M.D., and Harris R.C. Cyclooxygenase 2 and the kidney. Curr. Opin. Nephrol. Hypertens. 10 1 (2001) 89-98 (Jan)
7. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell Jr. J.E. Stat3 as an oncogene. Cell 98 (1999) 295-303
8. Brunello N., Alboni S., Capone G., Benatti C., Blom J.M., Tascedda F., Kriwin P., and Mendlewicz J. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int. Clin. Psychopharmacol. 21 4 (2006) 219-225
9. Cenci S., Weitzmann M.N., Roggia C., Namba N., Novack D., Woodring J., and Pacici R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J. Clin. Invest. 106 (2000) 1229-1237
10. Crowson A.N., and Magro C.M. Antidepressant therapy: a possible cause of atypical cutaneous lymphoid hyperplasia. Arch. Dermatol. 131 (1995) 925-929
11. Darnell Jr. J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
12. 1 cytokine interferon-γ, independent of monoamine transporter blockade. Eur. Neuropsychopharmacol. 16 (2006) 481-490
13. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., and Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12 (1998) 1063-1073
14. Fricker A.D., Rios C., Devi L.A., and Gomes I. Serotonin receptor activation leads to neurite outgrowth and neuronal survival. Mol. Brain Res. 138 2 (2005) 228-235
15. Garcia-Colunga J., Awad J.N., and Miledi R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 2041-2044
16. Gil-Ad I., Shtaif B., Levkovitz Y., Nordenberg J., Taler M., Korov I., and Weizman A. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Oncol. Rep. 15 1 (2006) 107-112
17. Hateboer G., Wobst A., Petersen O., Le Cam L., Vigo E., Sardet C., and Helin C. Cell cycle-regulated expression of mammalian CDC6 is dependent on E2F. Mol. Cell. Biol. 18 (1998) 6679-6697
18. Hauser P.J., Agrawal D., Hackney J., and Pledger W.J. STAT3 activation accompanies keratinocyte differentiation. Cell Growth Differ. 9 10 (1998) 847-855
19. Hestad K.A., Tonseth S., Stoen C.D., Ueland T., and Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J. ECT 19 4 (2003) 183-188
20. Horvath C.M. STAT proteins and transcriptional responses to extracellular signals. TIBS 25 (2000) 496-502
21. Irwin M. Psychoneuroimmunology of depression. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York, NY 983-988
22. Kirchherr H., and Küuhn-Velten W.N. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J. Chromatogr., B, Biomed. Sci. Appl. 843 (2006) 100-113
23. Luo F., Yee J.K., Huang S.H., Wu L.T., and Jong A.Y. Downregulation of human Cdc6 protein using a lentivirus RNA interference expression vector. Methods Mol. Biol. 342 (2006) 287-293
24. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 19 (1995) 11-38
25. Maes M., Scharpe S., Meltzer H.Y., Okayli G., Bosmans E., D'Hondt P., Vanden Bossche B.V., and Cosyns P. Increased neopterin and interferon-γ secretion and lower availability of l-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. 54 (1994) 143-160
26. Müller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Müller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Möller H.J., Arolt V., and Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11 (2006) 680-684
27. O'Brien S.M., Scully P., Fitzgerald P., Scott L.V., and Dinan T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 41 3-4 (2006) 326-331
28. Sedgwick J.D., and Czerkinsky C. Detection of cell-surface molecules, secreted products of single cells and cellular proliferation by enzyme immunoassay. J. Immunol. Methods 150 (1992) 159-175
29. Serafeim A., Grafton G., Chamba A., Gregory C.D., Blakely R.D., Bowery N.G., Barnes N.M., and Gordon J. 5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. Blood 99 (2002) 2545-2553
30. Serafeim A., Holder M.J., Grafton G., Chamba A., Drayson M.T., Luong Q.T., Bunce C.M., Gregory C.D., Barnes N.M., and Gordon J. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 15;101 8 (2003) 3212-3219
31. Sioud M. Main approaches to target discovery and validation. Methods Mol. Biol. 360 (2006) 1-12
32. Smith R.S. The macrophage theory of depression. Med. Hypotheses 35 (1991) 298-306
33. Stafford R.S., MacDonald E.A., and Finkelstein S.N. National patterns of medication treatment for depression, 1987 to 2001. Prim. Care Companion J. Clin. Psychiat. 3 (2001) 232-235
34. Stein M., Miller A.H., and Trestman R.L. Depression and the immune system. Arch. Gen. Psychiatry 48 (1991) 171-177
35. Tsao C.W., Lin Y.S., Chen C.C., Bai C.H., and Wu S.R. Cytokines and serotonin transporter in patients with major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30 5 (2006) 899-905
36. Wilfinger, W.W., Mackey, K., Chomczynski, P., 1997. Effect of pH and ionic strength on the spectrophotometric assessment of nucleic acid purity. Biotechniques. 22 (3), 474-476, 478-481.
37. Williams C.S., Mann M., and DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18 (1999) 7908-7916
38. Williams L., Bradley L., Smith A., and Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol. 172 (2004) 567-576
39. Xia Z., Karlsson H., DePierre J.W., and Nassberger L. Tricyclic antidepressants induce apoptosis in human T lymphocytes. Int. J. Immunopharmacol. 19 (1997) 645-654
40. Xia Z., Bergstrand A., DePierre J.W., and Nassberger L. The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J. Biochem. Mol. Toxicol. 13 6 (1999) 338-347
41. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 97 6 (2006) 439-447